Loading...
Prime Medicine, Inc.
PRME•NASDAQ
HealthcareBiotechnology
$1.69
$0.33(24.26%)
Prime Medicine, Inc. (PRME) Company Profile & Overview
Explore Prime Medicine, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Prime Medicine, Inc. (PRME) Company Profile & Overview
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
SectorHealthcare
IndustryBiotechnology
CEODr. Jeremy S. Duffield M.D., Ph.D.
Contact Information
Company Facts
214 Employees
IPO DateOct 20, 2022
CountryUS
Actively Trading